首页> 外国专利> COMPOSITION AND METHOD FOR PREDICTING RESPONSE TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS

COMPOSITION AND METHOD FOR PREDICTING RESPONSE TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS

机译:预测乳腺癌患者曲妥珠单抗治疗反应的组合物和方法

摘要

This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.
机译:预测曲妥珠单抗治疗的反应的组合物和方法技术领域本发明涉及用于预测乳腺癌患者对曲妥珠单抗治疗的反应的组合物和方法,更具体地,涉及通过使用多核苷酸预测曲妥珠单抗治疗的反应的组合物,试剂盒,DNA芯片和方法。各自包含由序列表中的SEQ ID NO:1至9、11至19和21至23中的任一个表示的核苷酸序列或通过用t,其突变体,其衍生物或片段取代u而从其衍生的核苷酸序列。其包含至少16个连续核苷酸的核苷酸,或包含其互补序列的多核苷酸,并使用Her2蛋白表达水平的升高或降低作为指标。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号